Omeros Corporation (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Analysts

Omeros Corporation (NASDAQ:OMER) has been given an average recommendation of “Moderate Buy” by the five analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $40.3333.

Several research firms recently issued reports on OMER. HC Wainwright raised their target price on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, January 27th.

Insiders Place Their Bets

In related news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Omeros

Large investors have recently modified their holdings of the company. State of Wyoming purchased a new stake in shares of Omeros during the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Omeros in the fourth quarter valued at approximately $33,000. Arax Advisory Partners raised its holdings in Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,894 shares during the period. Farther Finance Advisors LLC lifted its position in Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares in the last quarter. Finally, Osaic Holdings Inc. grew its stake in Omeros by 34.6% during the fourth quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 1,938 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Trading Down 1.1%

Shares of NASDAQ:OMER opened at $11.00 on Wednesday. The firm has a market cap of $779.90 million, a price-to-earnings ratio of -5.45 and a beta of 2.45. The stock’s 50-day moving average price is $11.71 and its two-hundred day moving average price is $9.46. Omeros has a 12-month low of $2.95 and a 12-month high of $17.65.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.